Sfoglia per AUTORE
VELLENGA E
Collezione AOU Città della Salute di Torino
Items : 2
Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. in HemaSphere / Hemasphere. 2020 Aug 12;4(4):e370. doi: 10.1097/HS9.0000000000000370. eCollection 2020 Aug.
2020
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Wester R; Zweegman S; van der Holt B; Kersten MJ; Vellenga E; van Marwijk-Kooy M; Asselbergs E; de Weerdt O; Minnema MC; Lonergan S; Palumbo A; Broijl A; Sonneveld P;
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. in Blood / Blood. 2015 Jan 15;125(3):449-56. doi: 10.1182/blood-2014-05-576256. Epub 2014 Nov 14.
2015
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Palumbo A; Lonergan S; de Weerdt O; Broyl A; van Marwijk-Kooy M; Vellenga E; Kersten MJ; van der Holt B; Asselbergs E; Zweegman S; Sonneveld P; Lokhorst H;